NCT07505498

Brief Summary

The systematic recording of patient-reported symptoms and health-related quality of life (patient-reported outcomes, PROs) is a central component of oncological care. Currently, however, screening for support needs in German hospitals is inconsistent and uses different assessment tools, leading to heterogeneity, redundant surveys, and limited comparability of results. This complicates standardized, patient-centered, and cross-sector care, as well as the early identification of therapy-associated side effects and support needs. The aim of the study is to investigate the acceptance and relevance of the core set of questions from the perspective of both cancer patients and professional healthcare providers. Cancer patient acceptance will be measured by the proportion of fully completed questionnaires, while cancer patient relevance will be assessed using a feedback form. The professional perspective will be gathered through guided feedback in quality circles conducted regularly in accordance with internal standards

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
900

participants targeted

Target at P75+ for all trials

Timeline
18mo left

Started Dec 2025

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress26%
Dec 2025Dec 2027

First Submitted

Initial submission to the registry

November 18, 2025

Completed
13 days until next milestone

Study Start

First participant enrolled

December 1, 2025

Completed
4 months until next milestone

First Posted

Study publicly available on registry

April 1, 2026

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2027

Expected
12 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

April 1, 2026

Status Verified

March 1, 2026

Enrollment Period

1.1 years

First QC Date

November 18, 2025

Last Update Submit

March 29, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • Proportion of Participants with Complete Core Question Set Completion at Baseline

    Description Acceptance is operationalised as the proportion of enrolled cancer patients who fully complete the predefined Scope-PRO core question set at baseline. Questionnaire completeness is used as an indirect indicator of acceptability. Unit of Measure Proportion (%)

    Baseline

  • Participant-Reported Acceptance Score (Study-Specific Acceptance Feedback Questionnaire) at Baseline

    Participant-reported acceptance is assessed using a study-specific feedback questionnaire evaluating comprehensibility, perceived burden, and overall acceptability of the core question set. Scale Study-specific Acceptance Feedback Questionnaire Range: 1 to 4 Higher scores indicate higher acceptance.

    Baseline

Secondary Outcomes (8)

  • Participant-Reported Relevance Score of the Core Question Set

    Baseline

  • Centre-Level Characteristics and Implementation Practices of PROM-Based Supportive Care Screening

    Baseline and last-patient-in at the respective institution

  • Severity of Prespecified Symptoms (Scope-PRO Core Question Set)

    Baseline

  • Psychological Distress Score (Scope-PRO Core Question Set)

    Baseline

  • Global Quality of Life Score (Scope-PRO Core Question Set)

    Baseline

  • +3 more secondary outcomes

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The study is intended for oncology patients before/during/after treatment in DKG-certified oncology centers and organ centers, as well as oncology practices cooperating with a DKG-certified organ or oncology center.

You may qualify if:

  • Age ≥ 18 years
  • Capacity to give consent
  • Cancer patients
  • Sufficient understanding of the German language

You may not qualify if:

  • Minors
  • Lack of capacity to give consent
  • Insufficient knowledge of German

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Medical Center Göttingen, Department of Gastroenterology, gastrointestinal oncology and endocrinology

Göttingen, 37075, Germany

RECRUITING

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident Physician

Study Record Dates

First Submitted

November 18, 2025

First Posted

April 1, 2026

Study Start

December 1, 2025

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

December 31, 2027

Last Updated

April 1, 2026

Record last verified: 2026-03

Locations